Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | AOC1 | P19801 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957033 | 1.00 | ALDH1A1 (0.45) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| SCHEMBL29958176 | 0.82 | GAA (0.46) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| SCHEMBL361105 | 0.82 | GAA (0.46) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| Hydrochloric Acid SCHEMBL29956207 | 0.80 | GAA (0.45) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| Hydrochloric Acid SCHEMBL1301715 | 0.80 | GAA (0.45) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| SCHEMBL29952734 | 0.74 | KDM4E (0.38) | KDM4ETDP1KDM4CEP300KAT2B | |
| SCHEMBL22489854 | 0.74 | KDM4E (0.38) | KDM4ETDP1KDM4CEP300KAT2B | |
| SCHEMBL708913 | 0.74 | SIRT3 (0.41) | MAPTTDP1GAACYP2D6CYP1A2 | |
| SCHEMBL115776 | 0.73 | GAA (0.46) | MAPTKDM4ETDP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL14797240 | 0.73 | SIRT3 (0.39) | TDP1GAACYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4368618-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-05-15 | — | — | EP | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20220013730-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK KGAA (DE) | 2022-01-13 | — | — | US | disclosed |
| WO-2020109434-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2020-06-04 | — | — | WO | disclosed |
| EP-2501695-B1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | UNIV MICHIGAN REGENTS (US) | 2018-08-29 | — | — | EP | disclosed |
| US-8815845-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120270862-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2501695-A2 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | The Regents Of The University Of Michigan (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011062766-A2 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220013730-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | ETV6, CYP2C19, ESR1 | ALDH1A1 175/4885MAPT 2534/4885KDM4E 2524/4885 |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | MALT1, CYP51A1, BCR | ALDH1A1 2301/4885MAPT 1950/4885KDM4E 949/4885 |
| US-20120270862-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | ROCK1, ROCK2, GABRR1 | ALDH1A1 1853/4885MAPT 1355/4885KDM4E 999/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | ALDH1A1 1189/4885MAPT 1383/4885KDM4E 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.